NorthWest Biotherapeutics Inc (NWBO)

[john1045]

This has been posted before but this abstract from Dr. Liau, Dr. Prins of UCLA and Dr. Bosch from Northwest Bio is a reminder of the results we can expect from our international Phase III GBM trial! (Link at Bottom)

Conclusions • Patients with evidence of disease recurrence immediately following 6 weeks of daily radiotherapy and chemotherapy after surgical resection of their brain tumor appear to survive
longer than would be expected based on data in the literature, when treated with DCVax-L.

• The apparent extended survival of these patients is seen in both Rapid Progressor Patients and Indeterminate Patients (as well as the Pseudo-Progressor Patient).
• The combined data suggest a possible survival benefit for patients with recurrent GBM conferred by the DCVax-L treatment.
• The ~30% of survivors who have lived beyond 2 years may reflect long term tumor control.
• DCVax-L treatment (vaccination of patients with autologous dendritic cells loaded with autologous tumor lysate antigens) also continues to have an excellent safety profile.

Prolonged Survival In Patients With Recurrent Glioblastoma Multiforme
Who Are Treated With Tumor Lysate-Pulsed Autologous Dendritic Cells
Marnix L. Bosch1, Robert Prins2 and Linda Liau2
1Northwest Biotherapeutics, Inc, and 2University of California, Los Angeles, USA

http://www.nwbio.com/NWBT_ITOC_poster_3-25-15.pdf